538 million years ago, evolution’s product team needed a new sensory vertical. What they shipped would reshape the competitive landscape for every animal on Earth — and it started as a bug report. This is the first entry in Ship It: How Biology Solved Everything by Solving Nothing.

MEETING MINUTES — SENSORY PRODUCTS DIVISION

Q3 Strategy Offsite — Primordial Soup Conference Room B

~538 Million Years Before Present

ATTENDEES:

  • Daryl, VP of Receptor Platforms
  • Karen, Director of Market Expansion
  • Todd, Senior Product Manager, Chemical Detection
  • Brenda, Marketing
  • Craig, IT (dialed in, mostly on mute)

DARYL: Alright, let’s get into it. Q2 numbers for the Chemical Detection platform are solid. Smell is performing. Taste is performing. The GPCR architecture is scaling beautifully. But leadership wants growth, and I’ve been asked to present a roadmap for new verticals by end of epoch. So. What else can we do with this thing.

TODD: We could do more smells. Worse smells. I want the record to reflect that we have not fully explored the worse-smells space.

DARYL: Todd.

KAREN: I’ve been looking at some interesting data from Field Testing. Apparently some of our users are reporting… sensations… when they’re in areas with high electromagnetic radiation. Like near the surface.

DARYL: What kind of sensations.

KAREN: Unclear. The receptors are doing something. It’s not smell. It’s not taste. It’s kind of a… twitch.

TODD: That’s a bug.

KAREN: What if it’s a feature.

TODD: It’s a bug. The receptor is detecting a chemical that isn’t there. That’s a malfunction. That’s literally what a malfunction is.

KAREN: What if we told the customer it was a feature.

BRENDA: I can brand that.

DARYL: Hold on. Karen, walk me through this. The GPCR is activating… without a ligand?

KAREN: No, the ligand’s there. It’s retinal. It’s already in the binding pocket. It just… does something when photons hit it.

TODD: When WHAT hit it.

KAREN: Photons. Little packets of —

TODD: I know what photons are, Karen. Why are photons activating a smell receptor.

KAREN: Because we left the ligand inside.

TODD: We left the ligand inside. And it works?

KAREN: It changes shape when light hits it, which activates the G-protein cascade just like a regular odorant binding event. Same downstream signaling, same second messenger amplification. Whole pipeline works. We don’t have to change anything on the backend.

DARYL: Wait. Nothing on the backend?

KAREN: Nothing. Same G-protein. Same cascade. Same neural integration stack. Craig, can you confirm?

CRAIG: (unmutes) Uh, yeah, the signal transduction layer doesn’t care where the activation event comes from. A GPCR is a GPCR. If the receptor says it’s activated, the system processes it. (mutes)

DARYL: So you’re telling me we can enter an entirely new sensory market with zero infrastructure investment.

KAREN: I am telling you that, yes.

BRENDA: What do we call it.

KAREN: We were thinking “light detection.”

BRENDA: Absolutely not.

KAREN: Photosensory integration?

BRENDA: I will jump into the ocean.

KAREN: …Vision?

BRENDA: What does that even mean?

KAREN: I don’t know. We made it up.

BRENDA: I love it. I can build a whole campaign around that. “Vision.” It’s abstract. It’s aspirational. Nobody knows what it means so nobody can say we’re not delivering on it.

DARYL: What’s the competitive moat?

KAREN: We superglued the ligand into the receptor.

DARYL: That’s the moat?

KAREN: That’s the moat.

TODD: I want to go back to the part where this is a bug.

DARYL: Todd, it’s a feature now.

TODD: We left the ligand inside the receptor by accident. The receptor is activating because of electromagnetic radiation, which is not what it was designed for. We are about to ship a product that works because of a manufacturing defect.

DARYL: Is it working?

TODD: …Technically.

DARYL: Then it’s a feature. Brenda, what’s the go-to-market look like?

BRENDA: Okay, so, I’m thinking we position this as a premium sensory experience. Totally new category. We don’t compare it to smell, we don’t compare it to taste, we act like we invented something from scratch.

TODD: We literally did not.

BRENDA: The customer doesn’t know that, Todd. The customer is a tube worm. The customer doesn’t know what a GPCR is. We say “revolutionary new platform,” we say “see the world in a whole new way,” we ship the exact same receptor with the ligand jammed inside, and we charge a premium because it reacts to the sun.

KAREN: There’s also a roadmap for variation.

DARYL: Variation?

KAREN: If we make three slightly different versions of the receptor — different amino acids in the binding pocket — each one responds to a different wavelength. Base model ships as monochrome. Variation is the premium tier.

BRENDA: That’s a subscription. I need this on the pricing page yesterday.

DARYL: What about the naming convention for the variations?

BRENDA: We let the customers name them. They’ll fight about it for millions of years. Free engagement.

DARYL: Brilliant.

TODD: I just want to be clear that my name is not on this.

DARYL: Your name is absolutely on this. This is a team win, Todd.

CRAIG: (unmutes) Hey, quick flag — some of the field testers are evolving a whole dedicated organ for this. Like, a sphere with a hole in it that focuses the photons. Thought you should know. (mutes)

DARYL: They’re building their own hardware?

KAREN: Yeah, that’s the beauty of it. We ship the receptor, they build the rest. Zero capex on our end. The sphere is a customer-funded integration.

DARYL: I need this in the deck for the board meeting.

BRENDA: Already on it. Working title: “Project Sunshine: Leveraging Existing Molecular Infrastructure to Disrupt the Electromagnetic Sensory Space.”

TODD: I hate every single one of you.

DARYL: That’s the spirit. Same time next epoch?

[POST-MEETING NOTE: “Vision” shipped in Q4 of the Cambrian period. Exceeded all expectations. Todd was promoted against his will.]